DNTH Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. (DNTH) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $1.8M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| CARR EDWARD 5 fills | CHIEF ACCOUNTING OFFICER | Sell 10b5-1 | 20,000 | $101.38 | $2.0M | 12,072 −62.4% of holding | |
| Read Simon | Director | Sell 10b5-1 | 2,778 | $117.55 | $326.6K | None left | |
| Veness Adam M | SVP, General Counsel and Sec. | Sell 10b5-1 | 16,167 | $110.38 | $1.8M | None left | |
| McGeorge Anne 5 fills | Director | Sell 10b5-1 | 7,750 | $109.01 | $844.8K | 6,300 −55.2% of holding | |
| Read Simon 6 fills | Director | Sell 10b5-1 | 2,777 | $109.55 | $304.2K | 2,707 −50.6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.